Patterns and significance of concomitant central and peripheral inflammatory demyelination

Neurological Research

Volumn 28, Issue 3, 2006, Pages 326-333

  Rezania, Kourosh ^a   Arnason, Barry G ^a   Soliven, Betty ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CIDP; Demyelination; GBS; Multiple sclerosis

Indexed keywords

ALPHA INTERFERON; ANTIGEN; BETA INTERFERON; CORTICOSTEROID; GLUCOCORTICOID; IMMUNOGLOBULIN; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DEMYELINATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMISPHERE; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; OPTIC NERVE; ORCHITIS; PERIPHERAL NERVOUS SYSTEM; PROGNOSIS; RELAPSE; REVIEW; SPINAL CORD; SYMPTOMATOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 33646814322     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X98233     Document Type: Review

References (115)

1. Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992; 31: 333-336
2. Beck CA, Metz LM, Svenson LW, et al. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 2005; 11: 516-519
3. Toyka KV, Gold R. The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents. Neurology 2003; 60: S2-S7
4. McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999; 46: 910-913
5. Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8: 157-165
6. Miglietta O, Lowenthal M. A study of peripheral nerve involvement in fifty-four patients with multiple sclerosis. Arch Phys Med Rehabil 1961; 42: 573-578
7. Striihuber A. iibet. Regenerations- und Proliferationsvorghge bei multipler Sklerose des Nervensystems. Beitr Pathol Anat 1903; 33: 409-412
8. Dinkler. Zur Kasuistik der multiplen Herdsklerose des Gehirns und Rückenmarks. D Zeitschr Nervenheilkunde 1904; 26: 233-247
9. Schob F. Ein Beitrag fur pathologischen Anatomic der Multiplen Sklerose. Monatsschr Psychiatr Neurol 1907; 22: 62-73
10. Schoene WC, Carpenter S, Behan PO, et al. 'Onion bulb' formations in the central and peripheral nervous system in association with multiple sclerosis and hypertrophic polyneuropathy. Brain 1977; 100: 755-773
11. Hasson J, Terry RD, Zimmerman HM. Peripheral neuropathy in multiple sclerosis. Neurology 1958; 8: 503-510
12. Pollock M, Calder C, Allpress S. Peripheral nerve abnormality in multiple sclerosis. Ann Neurol 1977; 2: 41-48
13. Shefner JM, Carter JL, Krarup C. Peripheral sensory abnormalities in patients with multiple sclerosis. Muscle Nerve 1992; 15: 73-76
14. Eisen A, Paty D, Hoirch M. Altered supernormality in multiple sclerosis peripheral nerve. Muscle Nerve 1982; 5: 411-414
15. Weir A, Hansen S, Ballantyne JP. Single fibre electromyographic jitter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1979; 42: 1146-1150
16. Grana EA, Kraft GH. Electrodiagnostic abnormalities in patients with multiple sclerosis. Arch Phys Med Rehabil 1994; 75: 778-782
17. Symond CP, Blackwood W. Spinal cord compression in hypertrophic neuritis. Brain 1962; 85: 251-262
18. Thomas PK, Walker RW, Rudge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain 1987; 110 (Pt 1): 53-76
19. Mendell JR, Kolkin S, Kissel JT, et al. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987; 37: 1291-1294
20. Ormerod IE, Waddy HM, Kermode AG, et al. Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: A clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatry 1990; 53: 789-793
21. Ohtake T, Komori T, Hirose K, et al. CNS involvement in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy. Acts Neurol Scand 1990; 81: 108-112
22. Ferbert A, Thron A. MRI lesions in younger healthy adults. J Neurol Neurosurg Psychiatry 1992; 55: 246
23. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38: 1822-1825
24. Feasby TE, Hahn AF, Koopman WJ, et al. Central lesions in chronic inflammatory demyelinating polyneuropathy: An MRI study. Neurology 1990; 40: 476-478
25. Laura M, Leong W, Murray NM, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: MRI study of brain and spinal cord. Neurology 2005; 64: 914-916
26. Waxman SG. Peripheral nerve abnormalities in multiple sclerosis. Muscle Nerve 1993; 16: 1-5
27. Pakalnis A, Drake ME, Jr, Barohn RJ, et al. Evoked potentials in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1988; 45: 1014-1016
28. Uncini A, Gallucci M, Lugaresi A, et al. CNS involvement in chronic inflammatory demyelinating polyneuropathy: An electrophysiological and MRI study. Electromyogr Clin Neurophysiol 1991; 31: 365-371
29. Stojkovic T, de Seze J, Hurtevent JF, et al. Visual evoked potentials study in chronic idiopathic inflammatory demyelinating polyneuropathy. Clin Neurophysiol 2000; 111: 2285-2291
30. Gigli GL, Carlesimo A, Valente M, et al. Evoked potentials suggest cranial nerves and CNS involvement in chronic relapsing polyradiculoneuropathy. Eur Neurol 1989; 29: 145-149
31. Feeney DJ, Pollard JD, McLeod JG, et al. HLA antigens in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1990; 53: 170-172
32. Hawkins SA, Cullen C, Middleton D, et al. HLA antigens and multiple sclerosis in Northern Ireland. Ir J Med Sci 1990; 159: 68-70
33. McDonald WI. Multiple sclerosis: Epidemiology and HLA associations. Ann N Y Acad Sci 1984; 436: 109-117
34. Koller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343-1356
35. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002; 59: S7-S12
36. Hemmer B, Kieseier B, Cepok S, et al. New immunopathologic insights into multiple sclerosis. Curr Neurol Neurosci Rep 2003; 3: 246-255
37. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121
38. Rezania K, Gundogdu B, Soliven B. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. Front Biosci 2004; 9: 939-945
39. McMahon EJ, Bailey SL, Castenada CV, et al. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005; 11: 335-339
40. Gamstorp I. Encephalo-myelo-radiculo-neuropathy: Involvement of the CNS in children with Guillain-Barre-Strohl syndrome. Dev Med Child Neurol 1974; 16: 654-658
41. Green SH. Polyradiculitis (Landry-Guillain-Barre syndrome) with total external ophthalmoplegia: Encephalo-myelo-radiculoneuropathy. Dev Med Child Neurol 1976; 18: 369-373
42. Lassmann H, Budka H, Schnaberth G. Inflammatory demyelinating polyradiculitis in a patient with multiple sclerosis. Arch Neurol 1981; 38: 99-102
43. Best PV. Acute polyradiculoneuritis associated with demyelinated plaques in the central nervous system: Report of a case. Acta Neuropathol (Berl) 1985; 67: 230-234
44. Amit R, Shapira Y, Blank A, et al. Acute, severe, central and peripheral nervous system combined demyelination. Pediatr Neurol 1986; 2: 47-50
45. Amit R, Glick B, Itzchak Y, et al. Acute severe combined demyelination. Childs Nerv Syst 1992; 8: 354-356
46. Kinoshita A, Hayashi M, Miyamoto K, et al. Inflammatory demyelinating polyradiculitis in a patient with acute disseminated encephalomyelitis (ADEM). J Neurol Neurosurg Psychiatry 1996; 60: 87-90
47. Okumura A, Ushida H, Maruyama K, et al. Guillain-Barre syndrome associated with central nervous system lesions. Arch Dis Child 2002; 86: 304-306
48. Goldschmidt B, Menonna J, Fortunato J, et al. Mycoplasma antibody in Guillain-Barre syndrome and other neurological disorders. Ann Neurol 1980; 7: 108-112
49. Kollet MH, West S, Davis DR, et al. Central and peripheral nervous system demyelination after infection with Mycoplasma pneumonia: Evidence of an autoimmune process. South Med J 1991; 84: 1255-1258
50. Nadkarni N, Lisak RP. Guillain-Barre syndrome (GBS) with bilateral optic neuritis and central white matter disease. Neurology 1993; 43: 842-843
51. Nishimura M, Saida T, Kuroki S, et al. Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 1996; 140: 91-95
52. Tan MJ, Chattophadyay AK, Griffiths PD, et al. Acute central and peripheral demyelination associated with Mycoplasma pneumoniae. Pediatr Neurol 2003; 29: 239-241
53. Susuki K, Odaka M, Mori M, et al. Acute motor axonal neuropathy after Mycoplasma infection: Evidence of molecular mimicry. Neurology 2004; 62: 949-956
54. Kumada S, Kusaka H, Okaniwa M, et al. Encephalomyelitis subsequent to mycoplasma infection with elevated serum anti-Gal C antibody. Pediatr Neurol 1997; 16: 241-244
55. Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barre syndrome: Relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48: 624-631
56. Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992; 31: 677-679
57. Suzuki T, Chiba A, Kusunoki S, et al. Anti-GQ1b ganglioside antibody and ophthalmoplegia of undetermined cause. Br J Ophthalmol 1998; 82: 916-918
58. Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 1999; 22: 1071-1074
59. Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 1999; 100: 3-12
60. Kornberg AJ, Pestronk A, Blume GM, et al. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes. Neurology 1996; 47: 1317-1320
61. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: Clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003; 126: 2279-2290
62. Behan PO, Lessell S, Roche M. Optic neuritis in the Landry-Guillain- Barre-Strohl syndrome. Br J Ophthalmol 1976; 60: 58-59
63. Toshniwal P. Demyelinating optic neuropathy with Miller-Fisher syndrome. The case for overlap syndromes with central and peripheral demyelination. J Neurol 1987; 234: 353-358
64. Pall HS, Williams AC. Subacute polyradiculopathy with optic and auditory nerve involvement. Arch Neurol 1987; 44: 885-887
65. Uncini A, Treviso M, Basciani M, et al. Associated central and peripheral demyelination: An electrophysiological study. J Neurol 1988; 235: 238-240
66. Phanthumchinda K, Intragumtornchai T, Kasantikul V. Guillain-Barre syndrome and optic neuropathy in acute leukemia. Neurology 1988; 38: 1324-1326
67. Carvalho AA, Galvao MD, Rocha MS, et al. [Miller fisher syndrome and optic neuritis: Case report]. Arq Neuropsiquiatr 2000; 58: 1115-1117
68. Colding-Jorgensen E, Vissing J. Visual impairment in anti-GQ1b positive Miller Fisher syndrome. Acta Neurol Scand 2001; 103: 259-260
69. Chan JW. Optic neuritis in anti-GQ1b positive recurrent Miller Fisher syndrome. Br J Ophthalmol 2003; 87: 1185-1186
70. Aimoto Y, Ito K, Moriwaka F, et al. Demyelinating peripheral neuropathy in Devic disease. Jpn J Psychiatry Neurol 1991; 45: 861-864
71. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993; 118: 83-87
72. Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve 2002; 26: 845-849
73. Yuki N, Wakabayashi K, Yamada M, et al. Overlap of Guillain-Barre syndrome and Bickerstaff's brainstem encephalitis. J Neurol Sci 1997; 145: 119-121
74. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33: 333-342
75. Kuwabara S, Ogawara K, Koga M, et al. Hyperreflexia in Guillain-Barre syndrome: Relation with acute motor axonal neuropathy and anti-GM1 antibody. J Neurol Neurosurg Psychiatry 1999; 67: 180-184
76. Kuwabara S, Nakata M, Sung JY, et al. Hyperreflexia in axonal Guillain-Barre syndrome subsequent to Campylobacter jejuni enteritis. J Neurol Sci 2002; 199: 89-92
77. Waksman BH, Adams RD. A comparative study of experimental allergic neuritis in the rabbit, guinea pig, and mouse. J Neuropathol Exp Neurol 1956; 15: 293-334
78. Levine S, Wenk EJ. Allergic neuritis induced in rats without the use of mycobacteria. Proc Soc Exp Biol Med 1963; 113: 898-900
79. Pender MP, Sears TA. Conduction block in the peripheral nervous system in experimental allergic encephalomyelitis. Nature 1982; 296: 860-862
80. Pender MP, Sears TA. Involvement of the dorsal root ganglion in acute experimental allergic encephalomyelitis in the Lewis rat. A histological and electrophysiological study. J Neurol Sci 1986; 72: 231-242
81. Stanley GP, Pender MP. The pathophysiology of chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Brain 1991; 114 (Pt 4): 1827-1853
82. McFarlin DE, Blank SE, Kibler RF. Recurrent experimental allergic encephalomyelitis in the Lewis rat. J Immunol 1974; 113: 712-715
83. Chalk JB, McCombe PA, Pender MP. Conduction abnormalities are restricted to the central nervous system in experimental autoimmune encephalomyelitis induced by inoculation with proteolipid protein but not with myelin basic protein. Brain 1994; 117 (Pt 5): 975-986
84. Chalk JB, McCombe PA, Smith R, et al. Clinical and histological findings in proteolipid protein-induced experimental autoimmune encephalomyelitis (EAE) in the Lewis rat. Distribution of demyelination differs from that in EAE induced by other antigens. J Neurol Sci 1994; 123: 154-161
85. Berger T, Weerth S, Kojima K, et al. Experimental autoimmune encephalomyelitis: The antigen specificity of T lymphocytes determines the topography of lesions in the central and peripheral nervous system. Lab Invest 1997; 76: 355-364
86. Weerth S, Berger T, Lassmann H, et al. Encephalitogenic and neuritogenic T cell responses to the myelin-associated glycoprotein (MAG) in the Lewis rat. J Neuroimmunol 1999; 95: 157-164
87. Williams RM, Lees MB, Cambi F, et al. Chronic experimental allergic encephalomyelitis induced in rabbits with bovine white matter proteolipid apoprotein. J Neuropathol Exp Neurol 1982; 41: 508-521
88. Yamamura T, Namikawa T, Endoh M, et al. Experimental allergic encephalomyelitis induced by proteolipid apoprotein in Lewis rats. J Neuroimmunol 1986; 12: 143-153
89. Brostoff SW, Powers JM, Weise MJ. Allergic encephalomyelitis induced in guinea pigs by a peptide from the NH2-terminus of bovine P2 protein. Nature 1980; 285: 103-104
90. Kadlubowski M, Hughes RA. The neuritogenicity and encephalitogenicity of P2 in the rat, guinea-pig and rabbit. J Neurol Sci 1980; 48: 171-178
91. Saida T, Saida K, Dorfman SH, et al. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 1979; 204: 1103-1106
92. Saida T, Saida K, Silberberg DH, et al. Experimental allergic neuritis induced by galactocerebroside. Ann Neurol 1981; 9 Suppl: 87-101
93. Raine CS, Traugott U, Farooq M, et al. Augmentation of immune-mediated demyelination by lipid haptens. Lab Invest 1981; 45: 174-182
94. Hoffman PM, Powers JM, Weise MJ, et al. Experimental allergic neuritis. I. Rat strain differences in the response to bovine myelin antigens. Brain Res 1980; 195: 355-362
95. Hayes SM, Knight KL. Group 1 CD1 genes in rabbit. J Immunol 2001; 166: 403-410
96. Moore GR, Traugott U, Farooq M, et al. Experimental autoimmune encephalomyelitis. Augmentation of demyelination by different myelin lipids. Lab Invest 1984; 51: 416-424
97. Saida T, Saida K, Silberberg DH. Demyelination produced by experimental allergic neuritis serum and anti-galactocerebroside antiserum in CNS cultures. An ultrastructural study. Acta Neuropathol (Berl) 1979; 48: 19-25
98. Kusunoki S, Yu RK, Kim JH. Induction of experimental autoimmune encephalomyelitis in guinea pigs using myelin basic protein and myelin glycolipids. J Neuroimmunol 1988; 18: 303-314
99. Van Schaik IN, Winer JB, De Haan R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; (2): CD001797
100. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobuiin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial. Lancet 2004; 364: 1149-1156
101. Fee DB, Fleming JO. Resolution of chronic inflammatory demyelinating polyneuropathy-associated central nervous system lesions after treatment with intravenous immunoglobulin. J Peripher Nerv Syst 2003; 8: 155-158
102. Di Trapani G, Carnevale A, Cioffi RP, et al. Multiple sclerosis associated with peripheral demyelinating neuropathy. Clin Neuropathol 1996; 15: 135-138
103. Krivickas LS, Hochberg FH, Freeman S. Chronic inflammatory demyelinating polyradiculoneuropathy with tumefactive central demyelination. Muscle Nerve 2006; 33: 283-288
104. Quan D, Pelak V, Tanabe J, et al. Spinal and cranial hypertrophic neuropathy in multiple sclerosis. Muscle Nerve 2005; 31: 772-779
105. Choudhary PP, Thompson N, Hughes RA. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995; 242: 252-253
106. Vallat JM, Hahn AF, Leger JM, et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology 2003; 60: S23-S28
107. Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 53: 1364-1365
108. Hadden RD, Sharrack B, Bensa S, et al. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53: 57-61
109. Sabatelli M, Mignogna T, Lippi G, et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995; 58: 638-639
110. Gorson KC, Allam G, Simovic D, et al. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 1997; 48: 777-780
111. Gorson KC, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998; 50: 84-87
112. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000; 23: 433-435
113. Pirko I, Kuntz NL, Patterson M, et al. Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination. Neurology 2003; 60: 1697-1699
114. Matsuse D, Ochi H, Tashiro K, et al. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis. Intern Med 2005; 44: 68-72
115. Rotta FT, Sussman AT, Bradley WG, et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000; 173: 129-139